Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 26 countries, Ajinomoto Co. had net sales of JPY 1,197.3 billion (USD 15.1 billion) in fiscal 2011. The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practice every day in order to implement the Ajinomoto Group Philosophy in accordance with the Ajinomoto Group Way. The Standards of Conduct also represent the commitments made to all stakeholders by Ajinomoto Group companies. Ajinomoto aim to be "a group of companies that contributes to human health globally" by continually creating unique value to benefit customers. To become a global group of food companies centered on the world's No. 1 seasoning business. To become a global group of aminoscience companies that contributes to humankind with the world's No. 1 amino acid technology. To become a group of health-promoting companies with a scientific approach to good taste and health.

Pharmaceuticals

Part of Mallinckrodt Plc, Mallinckrodt Veterinary, Inc. is an American company. The firm makes vaccines, growth agents and parasite-killing products. It was acquired by Schering-Plough Corp., a subsidiary of Merck & Co., Inc. since November 2009, from Mallinckrodt, Inc.(Old) on July 01, 1997 for $405 million.

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

AspiAir GmbH is developing inhaled treatments with acetylsalicylic acid in different indications.

Beijing Botai Weiming Biotechnology Co., Ltd., established on 2013-10-08, Business scope includes technology development,Technology Promotion,technical consulting,Technical Services,technology transfer;Sales of machinery and equipment,computer,Software and Auxiliary Equipment,Chemical Products(Does not contain dangerous chemicals and a class of precursor chemicals),stationery,electronic product;computer technology training;Natural science research and experimental development;Import and export,Technology Import and Export;sell food.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Sale of food and items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Hebei Huayang Biotechnology Co., Ltd., established on 2000-05-30, Business scope includes production,Sales of amino acid series products(food grade:Glycine,Glycine stock solution,DL-Alanine,L-Alanine,DL-Methionine,L-cystine,L-cysteine,L-cysteine ​​hydrochloride,L-Valine,L-arginine,L-Leucine,L-Tyrosine,L-threonine,L-Tryptophan,L-glutamic acid,L-Phenylalanine,L-Isoleucine,L-Methionine,L-Citrulline,L-Aspartic acid,L-Ornithine hydrochloride,disodium succinate<Scallops>,L-Ornithine,L-Glutamine,L-serine,beta-Alanine,L-Lysine,L-proline,L-Histidine,taurine,L-Histidine hydrochloride,L-Arginine hydrochloride,L-Asparagine,L-Theanine,L-Lysine hydrochloride;feed grade:L-Lysine hydrochloride,DL-Methionine,L-threonine,Glycine,L-Alanine)(Free of chemical hazards);Acting or distributing vitamins,sweetener,Food Additives and Raw Materials,Mechanical equipment and accessories;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Mitsui Chemicals, Inc. manufactures and sells petrochemicals and industrial inorganic chemical products. It operates through the following segments: Mobility, Healthcare, Food and Packaging, Base Material, and Others. The Mobility segment covers the new product development support business (solution business) for elastomers, functional compounds, functional polymers, polypropylene compounds, automobiles and other industrial products. The Healthcare segment includes vision care material, non-woven fabric, dental material, and personal care material. The Food and Packaging segment handles the coating and functional materials, functional films and sheets, and agricultural chemicals. The Base Material segment covers the ethylene, propylene, polyethylene, polypropylene, catalysts, phenols, high-purity terephthalic acid, PET resins, polyurethane materials, and industrial chemicals. The Others segment comprises of other related businesses. The company was founded on July 1, 1955 and is headquartered in Tokyo, Japan.

Ventaleon is developing inhaled treatments against viral infections. The Company’s lead therapy, is an inhaled LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well-known acetyl salicylic acid (Aspirin®), suitable as an ingredient for inhalable aerosol, has completed Phase II clinical trials to treat severe influenza. A proof-of-concept study in influenza patients with moderate to severe symptoms demonstrated more rapid symptom decline when administered via inhaled LASAG compared to standard of care. The Company is currently preparing to enter a pivotal clinical trial with inhaled LASAG. Ventaleon was founded as a spin-off from Activaero, a leading specialist in aerosol inhalation therapies and technologies, in 2012

Green Cross Co., Ltd. engages in the manufacture, sale, and rental of safety items. Its products include road safety materials, disaster prevention necessities, safety equipment, protection gear, and signboards and tags. The company was founded in January 1969 and is headquartered in Fukuoka, Japan.

Sunwin Biotech Shandong Co., Ltd. is a private company headquartered in Weifang, China. The firm manufactures and markets pharmaceutical intermediates, food and feed additive products.

Guangdong Blue Treasure Pharmaceutical Co., Ltd. is a Chinese joint venture company located in Qingyuan that manufactures pharmaceutical products.

Jinzhou Ahon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of medicine. Its products include calf serum deproteinized injection, penehyclidine hydrochloride injection, calf serum deproteinized enteric-coated capsules, glutamine granules, nervous system drugs, oncology drugs, perioperative drugs, and pediatric medicine. The company is headquartered in Jinzhou, China.

Beijing Northern Biotechnology Research Institute Co., Ltd., established on 1985-06-06, Business scope includes licensed projects:Class III medical device business;Production of Class III Medical Devices;Production of Class II Medical Devices;pharmaceutical production;medical service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Sales of Class I Medical Devices;Sales of Class II Medical Devices;Production of Class I Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export agency;advertisement making;Chemical product sales(No licensed chemical products);Socioeconomic Advisory Services;Business Management Consulting;Conference and Exhibition Services;market survey(Does not include foreign investigations).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Kaili Catalyst & New Materials Co., Ltd. engages in the research and development and production of precious metal catalysts. It specializes in research and development of catalytic application technology, and recovery and reprocessing of waste precious metal catalysts. Its products include palladium series of catalysts, platinum series catalyst, rhodium series catalysts, ruthenium series catalyst, and iridium series catalyst. Its products and services are used in medicine, new chemical materials, pesticides, dyes and pigments, environmental protection, new energy, electronics, and basic chemicals. The company was founded on March 15, 2002 and is headquartered in Xi'an, China.